A major five-year strategic drug discovery alliance, to discover and develop new cancer drugs, has been formed by Astex Pharmaceuticals, Cancer Research Technology Limited and Newcastle University.

ASTX528 is a novel small molecule CBP/p300 HAT domain inhibitor with potent in vivo activity and a favourable safety profile in preclinical species that was discovered by Astex using its proprietary ...

Kenilworth-based Merck announced on Monday an exclusive worldwide research collaboration and license agreement. “At Merck we continue to pursue new regimens designed to extend the benefits of highly ...

GlaxoSmithKline (GSK) has inked a deal with Astex Therapeutics to discover, develop, and commercialize compounds directed against multiple targets for £20 million (about $33 million) up front. Astex ...

NEW YORK (AP) -- Shares of Astex Pharmaceuticals Inc. rose Wednesday after the company said it received a $5.4 million payment from its partner Johnson & Johnson. THE SPARK: Astex said J&J's Janssen ...

Astex Pharmaceuticals has initiated phase 2, open-label, single-arm, clinical trials evaluating SGI-110 in the treatment of advanced hepatocellular carcinoma (HCC) patients who failed prior treatment ...

The University of Texas MD Anderson Cancer Center and Astex Pharmaceuticals, Inc., a wholly owned subsidiary of Otsuka Pharmaceutical Co. Ltd., based in Tokyo, Japan, today announce a strategic ...

Two years after FierceBiotech picked Astex Therapeutics in the UK as one of our Fierce 15 companies to watch, the biotech company is still rolling up impressive licensing deals with big pharma. Today ...

In the latest buyout of what’s been a busy M&A week, Japanese drug maker Otsuka inked an $886 million pact on Thursday to snag U.S. cancer treatment maker Astex (NASDAQ:ASTX). The deal will allow ...